Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 8;13:896628. doi: 10.3389/fphar.2022.896628

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ren, Zhang, Tao, Chen, Zou, Guo, Shen, Feng and Hu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Screen for optimal dosage of GJ-IF with rapid antidepressant potential. The low, medium, and high doses of GJ-IF are abbreviated as GJ-IFL, GJ-IFM, GJ-IFH. (A) Tail suspension test at 1 d after administration of GJ-IF. Immobility time was measured for the last 4 min during the 6 min testing time. One-way ANOVA, ^** p < 0.001, ^*** p < 0.001; control vs. GJ-IF. (B) Forced swim test at 1 d after administration of three doses of GJ-IF. One-way ANOVA, ^* p < 0.05; control vs. GJ-IF. (C) Unit food consumption during 10 min test of novelty suppressed-feeding at 1 d after administration of three doses of GJ-IF. One-way ANOVA, ^** p < 0.01; control vs. GJ-IF. (D) Time of latency to eat during 10 min test of novelty suppressed-feeding at 1 d after administration of three doses of GJ-IF. One-way ANOVA, ^** p < 0.01; control vs. GJ-IF.